Spyre Therapeutics (NASDAQ:SYRE) PT Raised to $40.00 at Wells Fargo & Company

Spyre Therapeutics (NASDAQ:SYREGet Free Report) had its price target lifted by investment analysts at Wells Fargo & Company from $35.00 to $40.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective points to a potential upside of 1.81% from the stock’s previous close.

SYRE has been the topic of a number of other research reports. BTIG Research raised their target price on shares of Spyre Therapeutics from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Stifel Nicolaus boosted their price objective on Spyre Therapeutics from $36.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th. Finally, Robert W. Baird assumed coverage on Spyre Therapeutics in a research note on Thursday, May 2nd. They set an “outperform” rating and a $50.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $43.17.

Check Out Our Latest Research Report on SYRE

Spyre Therapeutics Stock Performance

SYRE stock opened at $39.29 on Monday. The firm’s 50 day moving average price is $37.13. Spyre Therapeutics has a 12-month low of $2.66 and a 12-month high of $47.97. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of -0.55 and a beta of 2.93.

Spyre Therapeutics (NASDAQ:SYREGet Free Report) last issued its earnings results on Thursday, February 29th. The company reported ($2.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($1.80). On average, equities research analysts forecast that Spyre Therapeutics will post -2.36 earnings per share for the current fiscal year.

About Spyre Therapeutics

(Get Free Report)

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).

Featured Stories

Analyst Recommendations for Spyre Therapeutics (NASDAQ:SYRE)

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.